查看文章

Fanconi anemia (FA) is a rare autosomal recessive or X-linked syndrome that is characterized by bone marrow failure and congenital abnormalities. Allogeneic bone marrow transplantation (BMT) is currently the only cure for the hematological complications associated with FA [1, 2]. Alemtuzumab is a monoclonal antibody directed against CD52-positive cells used in some of the pre-BMT conditioning regimens. This drug has been associated with autoimmune thyroid disease (ATD) in approximately a third of treated patients with multiple sclerosis (MS)[3–5]. Three cases of new onset ATD have been reported after the use of alemtuzumab in pediatric patients following allogeneic BMT for sickle cell disease [6]. Less than ten cases of thyroid eye disease following alemtuzumab therapy have been reported in patients with MS [7–9], but none in patients with BMT. In this article, we report a case of a patient who developed …